BioAdvance News

GenPro presents azacitidine efficacy study to identify epigenetic predictors of Responder vs Non-Responder AML/MDS patients

By WebmasterNovember 1, 2016November 1st, 2024No Comments

GenPro presents azacitidine efficacy study to identify epigenetic predictors of Responder vs Non-Responder AML/MDS patients

Previous PostCohero Health Closes Series A Funding to Accelerate Commercial Expansion
Next PostGenPro publishes EpiMarker feasibility study revealing distinct epigenetic signature of Parkinson's Disease in blood